OBJECTIVES: The main objective is the study of the evolution of the number of incident cases of prostate cancer in France from 2001 to 2012 from 5 hospital centers of urology.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The secondary objective is to describe the characteristics of the incident cases and to compare them to those of the patients of the national registers of cancer for the period.
MATERIAL AND METHODS: Prospective observational multicentric study from 01/01/2001 to 31/12/2012 of databases in 5 French, public and private hospital centers of urology. The inclusive centers were selected outside departments with cancer register. The collected data were the prostatic biopsies performed in every center and the number of positive biopsies. The biopsies in cases of already known cancer and in re-evaluation were excluded. The data of age and stage (PSA and Gleason grade) were collected. The estimation of the incidence standardized in France is established after a period of observation of 3 years. The data updated in 2009 show a peak of incidence in 2005 then a decrease from 2006 (64,518 cases) until 2009 (53,465 cases). The median age in the diagnosis was of 70 years in 2005.
RESULTS: Overall, 18,392 prostatic biopsies were included in the analysis. The average rate of positive biopsies was stable over the period 51.41% (IQR 0,02). The total number of cases of positive biopsies increased from 2001 to 2007 (482 cases in 1028 cases) in 2007, then decreased from 2008 to 2012 (649 cases). There was no difference in this variation between the centers. The median age in the diagnosis was of 70 years (EIQ=1.5) in 2001 and 68 years (EIQ=2.75) in 2012. PSA at diagnosis was< 10ng/mL in 65% of cases and 10 to 20ng/mL in 22% of cases in 2012. The population of patients of the study differed significantly from that of FRANCIM on the distribution by age ranges (year 2005, P< 0.0001 and year 2009, P< 0.001), which explains the gap of one year (on 2007 instead of 2006) of the peak of incidental cases.
CONCLUSION: The evolution of the number of incidental cases of prostate cancer in France from 2001 to 2012 from hospital data of 5 centers are similar to those of the network of registers representative of the French population. This observed evolution represents data available for cancer registers to estimate incidence variation between 2 publications.
Helfrich O, Crouzet S, Ruffion A, Houlgatte A, Cavillon C, Gerard C, Villers A. Are you the author?
Service d'urologie, université Lille-Nord-de-France, CHU de Lille, 59000 Lille, France; Centre hospitalier Lyon-sud, hospices civiles de Lyon, 69310 Lyon, France; Hôpital Edouard-Herriot, hospices civiles de Lyon, 69003 Lyon, France; Hôpital d'instruction des Armées Val-de-Grâce, 75005 Paris, France; Polyclinique Saint-François - Saint-Antoine, 03100 Montluçon, France; Clinique Océane, 56000 Vannes, France; 6 Kyoto Prefectural University of Medicine, 602-0841 Kyoto, Japon.
Reference: Prog Urol. 2014 Dec 3. pii: S1166-7087(14)00561-2.
Article in French.